Bioequivalence of Isosorbide Mononitrate Sustained Tablets in Chinese Healthy Volunteers
JI Hong-ying
Abstract
JI Hong-ying
Abstract
OBJECTIVE:To evaluate the bioequivalence of two kinds of isosorbide mononitrate sustained tablets in Chinese healthy volunteers.METHODS:According to two formulas double period crossover protocol,a total of 18 healthy volunteers were orally administered with test prepartion(T)or reference preparation(R)(40mg),1w later,they were administered with R or T by a crossover way.For multidoese trial,the patients received T or R 40mg every morning for 6 consecutive days.Blood samples were taken at 4-6 days before oral administration in the morning,and according to the protocal,the blood samples were taken at 6d after oral administration.Serum concentrations of isosorbide mononitrate were measured with validated GC-ECD.The pharmacokinetic parameters and bioavailability of two isosorbide mononitrate sustained tablets were calculated and the bioequivalence was evaluated.RESULTS:The main pharmacokinetic parameters of tested and reference isosorbide mononitrate sustained tablet in volunteers administrated with an oral single dose of 40mg were as follows:T max(4.9±1.6)and(4.9±1.2)h,C max(719.42±183.72)and(726.52±177.55)ng·mL-1,t_ 1/2(3.9±0.6)and(3.7±0.9)h,AUC_ 0-t(5 687.38±1 271.64)and(5 586.05±1 290.01)ng·h·mL-1,AUC_ 0-∞(5 831.67± 1 308.47)and(5 719.20±1 329.54)ng·h·mL-1,and computed based on AUC_ 0-t,the relative bioavailability of tested isosorbide mononitrate sustained tablet was(103.0±17.1)%.The main pharmacokinetic parameters of tested and reference isosorbide mononitrate sustained tablet in volunteers administrated with oral multi-dose of 40 mg were as follows:T max-ss(4.9±1.4)and(4.9±1.5)h,C max-ss(745.43±143.83)and(747.55±130.72)ng·mL-1,AUC ss(7 860.24± 1 827.46)and(8 104.13±1 637.35)ng·h·mL-1,and the relative bioavailability of tested isosorbide mononitrate sustained tablet was(97.1±10.9)%.Tested with Wilcoxon(T max),ANOVA and two one-sided t test(AUC,C max),the main pharmacokinetic parameters of tested and reference isosorbide mononitrate sustained tablets showed no significant differences.The 90% confidential intervals of C max and AUC_ 0-t of tested formula were 93.26%~104.33% and 95.10%~108.83%,respectively.The 90% confidential intervals of C max-ss and AUC ss of tested formula were 93.97%~105.01% and 92.24%~101.08%,respectively.CONCLUSION:Two kinds of isosorbide mononitrate sustained tablets are bioequivalent.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
OBJECTIVE:To evaluate the bioequivalence of two kinds of isosorbide mononitrate sustained tablets in Chinese healthy volunteers.METHODS:According to two formulas double period crossover protocol,a total of 18 healthy volunteers were orally administered with test prepartion(T)or reference preparation(R)(40mg),1w later,they were administered with R or T by a crossover way.For multidoese trial,the patients received T or R 40mg every morning for 6 consecutive days.Blood samples were taken at 4-6 days before oral administration in the morning,and according to the protocal,the blood samples were taken at 6d after oral administration.Serum concentrations of isosorbide mononitrate were measured with validated GC-ECD.The pharmacokinetic parameters and bioavailability of two isosorbide mononitrate sustained tablets were calculated and the bioequivalence was evaluated.RESULTS:The main pharmacokinetic parameters of tested and reference isosorbide mononitrate sustained tablet in volunteers administrated with an oral single dose of 40mg were as follows:T max(4.9±1.6)and(4.9±1.2)h,C max(719.42±183.72)and(726.52±177.55)ng·mL-1,t_ 1/2(3.9±0.6)and(3.7±0.9)h,AUC_ 0-t(5 687.38±1 271.64)and(5 586.05±1 290.01)ng·h·mL-1,AUC_ 0-∞(5 831.67± 1 308.47)and(5 719.20±1 329.54)ng·h·mL-1,and computed based on AUC_ 0-t,the relative bioavailability of tested isosorbide mononitrate sustained tablet was(103.0±17.1)%.The main pharmacokinetic parameters of tested and reference isosorbide mononitrate sustained tablet in volunteers administrated with oral multi-dose of 40 mg were as follows:T max-ss(4.9±1.4)and(4.9±1.5)h,C max-ss(745.43±143.83)and(747.55±130.72)ng·mL-1,AUC ss(7 860.24± 1 827.46)and(8 104.13±1 637.35)ng·h·mL-1,and the relative bioavailability of tested isosorbide mononitrate sustained tablet was(97.1±10.9)%.Tested with Wilcoxon(T max),ANOVA and two one-sided t test(AUC,C max),the main pharmacokinetic parameters of tested and reference isosorbide mononitrate sustained tablets showed no significant differences.The 90% confidential intervals of C max and AUC_ 0-t of tested formula were 93.26%~104.33% and 95.10%~108.83%,respectively.The 90% confidential intervals of C max-ss and AUC ss of tested formula were 93.97%~105.01% and 92.24%~101.08%,respectively.CONCLUSION:Two kinds of isosorbide mononitrate sustained tablets are bioequivalent.
Key concepts: Bioequivalence, Isosorbide mononitrate, Bioavailability, Pharmacokinetics, Medicine, Crossover study, Oral administration, Pharmacology